



a.) Amendment to the Claims

Claims 1-20 (Cancelled).


21. (Previously Presented) A method of treating an anxiety disorder, comprising administering, to a human in need thereof, an effective amount of a xanthine derivative represented by formula (I-A):



[wherein R<sup>1a</sup> and R<sup>2a</sup> independently represent methyl or ethyl; R<sup>3a</sup> represents hydrogen or lower alkyl; and Z<sup>a</sup> represents formula (I-ii)]




(in which R<sup>6</sup> represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an integer of 1 to 3) or formula (I-iii)




(in which at least one of R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> represents lower alkyl or lower alkoxy and the others represent hydrogen; R<sup>10</sup> represents hydrogen or lower alkyl)],

or a pharmaceutically acceptable salt thereof.

22. (Currently Amended) A method of treating an anxiety disorder, comprising administering, to a human in need thereof, an effective amount of a xanthine derivative represented by formula (I-B):



wherein [wherein R<sup>1b</sup> and R<sup>2b</sup> independently represent hydrogen, propyl, butyl, lower alkenyl or lower alkynyl; R<sup>3b</sup> represents hydrogen or lower alkyl; Y<sup>1</sup> and Y<sup>2</sup> independently represent hydrogen, halogen or lower alkyl; and Z<sup>b</sup> represents substituted or unsubstituted naphthyl, or formula (I-ii)



(in which R<sup>6</sup> represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an integer of 1 to 3)]

or a pharmaceutically acceptable salt thereof.

23. (Previously Presented) A method of treating an anxiety disorder, comprising administering, to a human in need thereof, an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof.

24. (Previously Presented) The method of treating an anxiety disorder according to any one of claims 21 to 23, wherein the anxiety disorder is generalized anxiety disorder.

25. (Previously Presented) A method of treating an anxiety disorder, comprising administering an effective amount of at least one xanthine derivative or pharmaceutically acceptable salt thereof according to any one of claims 21 to 23 in combination with an anxiolytic which does not have adenosine A<sub>2A</sub> receptor antagonist activity.

Claims 26-30 (Cancelled).

31. (Previously Presented) The method of treating an anxiety disorder according to any one of claims 21 to 23, wherein the anxiety disorder is panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder or specific phobia.

Claims 32-68 (Cancelled).

69. (Previously Presented) The method of treating an anxiety disorder according to claim 25, wherein the anxiety disorder is generalized anxiety disorder.

70. (Previously Presented) The method of treating an anxiety disorder according to claim 25, wherein the anxiety disorder is panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder or specific phobia